Test ID: PFK1 Phosphofructokinase Enzyme Activity, Blood
Specimen Required
Collection Container/Tube:
Preferred: Yellow top (ACD solution B)
Acceptable: Lavender top (EDTA)
Specimen Volume: 6 mL
Collection Instructions: Send specimen in original tube. Do not transfer blood to other containers.
Useful For
Evaluation of individuals with Coombs-negative nonspherocytic hemolytic anemia
Evaluation of individuals with exercise intolerance or myopathy
Genetic studies in families with phosphofructokinase deficiency
Method Name
Kinetic Spectrophotometry
Reporting Name
Phosphofructokinase, BSpecimen Type
Whole Blood ACD-BSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood ACD-B | Refrigerated | 11 days |
Clinical Information
Phosphofructokinase (PFK) is the third enzyme in glycolysis. It converts fructose-6-phosphate to fructose 1,6-diphosphate. PFK deficiency, also called glycogen storage disease, type VII or Tarui disease (OMIM 232800), is a rare hereditary autosomal recessive disorder that is typically noticed in childhood. Different clinical subtypes (classical, late-onset, infantile and hemolytic) have been described. Manifestations can vary, including exercise intolerance, exertional myopathy, nausea, stiffness, and myoglobinuria. Although not classically described, a second-wind effect is noticed by some patients.(1) A subset of individuals have compensated (high normal hemoglobin values) or mild hemolytic anemia, episodic jaundice, hyperuricemia, or gout-like symptoms. No distinctive morphologic abnormalities are seen on the peripheral blood smear. Red blood cell PFK activity is typically partially decreased (30-50% mean normal) and muscle biopsy PFK activity is markedly decreased.
Reference Values
≥12 months of age: 5.8-10.9 U/g Hb
Reference values have not been established for patients who are <12 months of age.
Interpretation
Clinically significant disorders due to phosphofructokinase deficiency are associated with red blood cell activity levels less than 50% of mean normal. Unaffected heterozygotes have been reported with levels of 63% of normal. Therefore, genetic correlation will often be important in ambiguous cases.
Clinical Reference
1. Sherman JB, Raben N, Nicastri C, et al: Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency. Am J Hum Genet. 1994 Aug;55(2):305-313
2. Tarui S, Okuno G, Ikura Y, Tanaka T, Suda M, Nishikawa M: Phosphofructokinase deficiency in a skeletal muscle. A new type of glycogenosis. Biochem Biophys Res Commun. 1965 May 3;19:517-23. doi: 10.1016/0006-291x(65)90156-7
3. Musumeci O, Bruno C, Mongini T, et al: Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012 Apr;22(4):325-330
4. Nakajima H, Raben N, Hamaguchi T, Yamasaki T: Phosphofructokinase deficiency; past, present and future. Curr Mol Med. 2002 Mar;2(2):197-212. doi: 10.2174/1566524024605734
5. Auranen M, Palmio J, Ylikallio E, et al: PFKM gene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurol Genet. 2015 Jun 4;1(1). doi: 10.1212/NXG.0000000000000007
6. Raben N, Sherman JB: Mutations in muscle phosphofructokinase gene. Hum Mutat. 1995;6(1):1-6. doi: 10.1002/humu.1380060102
7. Koralkova P, van Solinge WW, van Wijk R: Rare hereditary red blood cell enzymopathies associated with hemolytic anemia-pathophysiology, clinical aspects and laboratory diagnosis. Int J Lab Hematol. 2014 Jun;36:388-397. doi: 10.1111/ijlh.12223
CPT Code Information
82657
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PFK1 | Phosphofructokinase, B | 72664-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
PFKCL | Phosphofructokinase, B | 72664-6 |
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Day(s) Performed
Tuesday, Thursday
Report Available
1 to 6 daysForms
If not ordering electronically, complete, print, and send a Benign Hematology Test Request (T755) with the specimen.
mml-benign-hematology-disorders